¿Quiénes somos? ¿Dónde estamos? Contacta ¿Qué es la MBE? Aviso Legal
 
 
Pautas/ Referencias Pautas/ Referencias
 

REFERENCIAS MÁS RECIENTES Y MÁS RECOMENDADAS

Otras guías:

  • Diagnosis and management of lung cancer, 3RD ED: ACCP Guidelines. journal.publications.chestnet.org CHEST. MAY 2013 SUPPLEMENT

  • Guías NCCN 2010: www.nccn.org.

  • Guías ESMO 2010: Ann Oncol suplemento mayo 2010

  • Guías SEOM 2010
  • Guías NICE 2005 (Update marzo 2011)

  • Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ. 2011

  • Guidelines on the radical management of patients with lung cancer. British Thoracic Society; Society for Cardiothoracic Surgery in Great Britain and Ireland. Thorax. 2010

  • SEPAR guidelines for lung cancer staging. Arch Bronconeumol. 2011.

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011.

  • Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health. 2012

  • The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012.

  • American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013

  • Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013.

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011

  • Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Ann Oncol. 2012

Subir

Serie de artículos de la Asociación Internacional para el Estudio del Cáncer de Pulmón (IASLC), con la participación del Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y de Cirugía Torácica (GCCB-S) para la nueva Estadificación TNM – Estadios de 2010:

The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.
Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions.
J Thorac Oncol. 2009 Sep;4(9):1049-59.

The IASLC Lung Cancer Staging Project: data elements for the prospective project.
Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee. J Thorac Oncol. 2009 Jun;4(6):679-83.

The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.
Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P; Members of IASLC Staging Committee. J Thorac Oncol. 2009 May;4(5):568-77.

The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer.
Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P; International Staging Committee and Participating Institutions. J Thorac Oncol. 2008 Nov;3(11):1213-23.

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.
Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. J Thorac Oncol. 2007 Dec;2(12):1067-77.

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. J Thorac Oncol. 2007 Aug;2(8):706-14. Erratum in: J Thorac Oncol. 2007 Oct;2(10):985.

The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.
Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, Goldstraw P; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. J Thorac Oncol. 2007 Aug;2(8):694-705.

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer.
Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr, Yokomise H; International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. J Thorac Oncol. 2007 Aug;2(8):686-93.

The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.
Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, Tsuchiya R, Vansteenkiste J; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. J Thorac Oncol. 2007 Jul;2(7):603-12.

The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer.
Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallières E, Goldstraw P; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. J Thorac Oncol. 2007 Jul;2(7):593-602.

Subir

REFERENCIAS CITADAS EN EL TEXTO

Estando conectado a internet, un click sobre la mayoría de las citas, facilita el acceso directo al resumen de Pubmed.

1- Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 1059-68 .

1B- Travis WD, Brambilla E, Muller-Hermerlink HK et al. Tumours of the lung. In Travis WD eds. World Health Organization Classification of Tumours. Pathology ang Genetics of the lung, pleura and hearth. Lyon: IARC Press 2004:9-124

1C- Travis WD, Brambilla E, et al. Task Force ATS-ERS-IASLC. Classification of Adenocarcinoma. J Thorac Oncol (en prensa)

1D- Estrada Trigueros G, et AL. Bronchogenic carcinoma 2000-2001: characteristics and overall survival. Arch Bronconeumol 2007;43:594-8.

1E- Survival of 2,991 patients with surgical lung cancer: the denominator effect in survival. Duque JK, López-Encuentra A, Porta RR; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery. Chest. 2005 Oct;128(4):2274-81.

2 - López Encuentra A, Martínez González del Río J, Cortes Funes H. Protocolo clínico para el estudio y tratamiento del carcinoma broncogénico. Med Clin (Barc) 1979; 72: 321-331
79243157

3 - López Encuentra A. Carcinoma Broncogénico. En: Martín Escribano P, López Encuentra A (eds). Diagramas Neumología. IDEPSA. Madrid. 1989.

4 - López Encuentra A, Linares Asensio MJ. Carcinoma Broncogénico. En: Martín Escribano P, López Encuentra A (eds). Pautas de Práctica Clínica en Neumología. Algoritmos clínicos y procedimientos. IDEPSA. Madrid. 1996

5-Grupo Cooperativo Médico Quirúrgico de Carcinoma Broncogénico del Hospital Universitario 12 de Octubre. Pauta Carcinoma Broncogénico. Edición 2007. http://www.mbeneumologia.org/pautaCB (accesible en septiembre 2010)

6- Alberts WM, Bepler G, Hazelton T, et al; American College of Chest Physicians. Lung cancer. Practice organization. Chest 2003; 123 (1 Suppl): 332S-337S.

7 - Gospodarowicz MK, Henson DE, Hutter RVP, et al (eds). Prognostic factors in cancer. Second edition. Wiley-Liss. New York. 2001.

7B- Birim O, Kappetein AP, Waleboer M, Puvimanasinghe JP, Eijkemans MJ, Steyerberg EW, Versteegh MI, Bogers AJ.Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 2006; 132: 491-8.

7C- Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.

7D- Lee ES et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-404.

7E- López-Encuentra A el al, on behalf of the Bronchogenic Carcinoma Cooperati­ve Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Composite anatomic-clinical-molecular prognostic model in non-small cell lung cancer. A multicenter study of 512 patients. Eur Respir J 2010 (en prensa)

8- Putnam JB. The anatomic basis for lung cancer staging: the end of the beginning? Ann Thorac Surg 2001; 71: 1757-1758

8B- Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-42.

8C- Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118: 963-9.

9- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 ;350: 2129-39.

9B- Olaussen KA, Dunant A, Fouret P, et al.; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.

Subir

10- Pozo Rodríguez F, Martín de Nicolas JL, Sánchez Nistal A, et al; Study Group for PET-Staging in Lung Cancer. Diagnostic accuracy of helical CT and FDG-PET for identifying lymph node mediastinal metastasis in patients with potentially resectable non-small cell lung cancer. J Clin Oncol 2005; 23: 8348-56. 

10B- Alonso Moralejo R, et al. Use of Positron Emission Tomography in Assessing Hidden Extrathoracic Metastasis in Non Small Cell Lung Cancer. Arch Bronconeumol 2010;46: 238-43

10C- Alonso Moralejo R, et al. Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging. Eur Resp J 2007;30:430s

11- British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain, and Ireland Working Party. Guidelines on the selection of patientes with lung cancer for surgery. Thorax 2001; 56: 89-108.

12- ACCP Evidence-Based Guidelines. Diagnosis and management of lung cancer. Chest 2003; 123 (Suppl). January.

13- Detterbeck FC, Rivera MP, Socinski MA (Eds). Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia. PA. WB Saunders. 2001.

13B- Lung cancer: diagnosis and treatment. NICE Clinical Guideline. Data issued: 2-2005. Expected review date: 2-2009.www.nice.org.uk/page.aspx?o=244008#documents

13C- Azzoli. Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27: 6251-66.

13D- Servicio Neumología Hospital Universitario 12 de Octubre. Sospecha Cáncer de Pulmón. Enero 2007. http://www.mbeneumologia.org/AP-AEN

14- Comisión de Tumores Hospital Universitario 12 de Octubre. Informe del Registro de Tumores. Hospital Universitario 12 de Octubre. 2000.

15- González Garrido F, Montoro Zulueta FJ, Rey Terrón L, et al. Estudio descriptivo de las características del carcinoma broncogénico en un hospital terciario. Arch Bronconeumol 2001; 37 (sup1): 70-71.

15B- García Quero C et  al. Profitability of the bronchoscopy in the diagnosis of focal pulmonary malignant lesions. Rev Clin Esp 2008;208:551-6.

17- Pozo Rodríguez F. Estudio ELCAP. TAC-Baja Radiación y screening del carcinoma broncogénico I. Casos prevalentes.  www.mbeneumologia.org.

18- Alvarez Martinez C. FDG-PET en el diagnóstico de lesiones pulmonares focales.  www.mbeneumologia.org.

19- Pozo Rodríguez F,  Álvarez Martínez C, Melero Moreno C. Revisión sistemática de la eficacia diagnóstica de la Tomografía por Emisión de Positrones en el Nódulo Pulmonar Solitario. www.mbeneumologia.org.

20- Postmus PE, Rocmans P, Asamura H, et al. Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer 2003; 42 (Suppl 1  9: S3-6.

21- de Miguel Poch, E. TAC torácica antes de la broncoscopia en pacientes con sospecha de carcinoma broncogénico. www.mbeneumologia.org

21B- Holty JE, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis. Thorax 2005; 60: 949-55.

21B2- Herth FJ, Rabe KF, Gasparini S, Annema JT.Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions. Eur Respir J 2006; 28: 1264-75.

21B3- Bernasconi M, Chhajed PN, Gambazzi F, et al. Combined transbronchial needle aspiration and positron emission tomography for mediastinal staging of NSCLC. Eur Respir J 2006; 27: 889-94.

Subir

21C- Albain KS et al. North American Lung Cancer Intergroup Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005; 23 (16s): 624S.

21D- Conde E, Angulo B, Redondo P, Toldos O, García-García E, Suarez-Gauthier A, Rubio-Viqueira B, Marrón C, García-Lujan R, Sánchez-Céspedes M, López-Encuentra A, Paz-Ares L, López-Ríos F. The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung. PLoS ONE 2010; 5(8): e12209.

21E- Nicholson AG et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-41.

21F- Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. Engl J Med 2009;361:958-67.

21G- GCCB-H12X. Clasificación molecular del CB. 2010 (documento interno)

21H- Brambilla E. Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. Eur Respir J 2010;35:717-20.

21J- Pirker R, Popper, HH. New Concepts in pulmonary oncology. Eur Respir Mon 2007;39:63

21K- Pirker R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.

21L- Bunn PA Jr, et al. Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol 2010;5:1113-5.

22- Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125: 2300-8.

22B- Travis WD, et al. The new IASC-ATS-ERS international multidisciplinar lung adenocarcinoma classification. J Thorac Oncol (en prensa)

22C- Travis WD, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-4.

22D- West H, et al. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009; 136:1112-8.

22E- Roberts PJ, et al. Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy? J Clin Oncol 2010 Oct 4. [Epub ahead of print]

22F- Pirker R, and European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010; 5:1706-13.

23- Booton R, Jones M, Thatcher N. Lung cancer 7: management of lung cancer in elderly patients. Thorax. 2003; 58: 711-20.

24- van Meerbeeck JP, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patients with right-sided lung cancer. Eur Respir J 2002; 19: 141-5.

25- Varela G, Roca R, Boagert M, et al. Toracotomía por carcinoma broncogénico en pacientes mayores de 70 años. Arch Bronconeumol 1988; 24: 67-72.

26- Varela Simo G, Toledo J. Pulmonary resection for lung cancer in the elderly. Current topics in General Thoracic Surgery. Vol 2. Elsevier, Amsterdam, 1992: 160-164.

27-Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest. 2003; 123: 2096-103.

Subir

27b- Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg 2004; 77: 271-7.

28 - López Encuentra A, and Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Comorbidity in operable lung cancer. A multicenter descriptive study on 2992 patients. Lung Cancer 2002; 35: 263-9.

29- López Encuentra A. Comorbilidad como factor pronóstico en carcinoma broncogénico no microcítico estadio Ip resecado. www.mbeneumologia.org

30- Sculier JP, Fry WA (Eds). Malignant tumors of the lung. Evidence-based management. Springer. Berlín. 2004.

31- Smit EF, Groen HJM, Timens W, et al. Surgical resection for small cell carcinoma of the lung: a retrospective study, et al. Thorax 1994; 49: 20-22

32 - Shepherd FA, Ginsberg RJ, Feld R, et al. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. J Thorac Cardiov Surg 1991; 101: 385-393. 91155399

33- Asamura H, Ginsberg RJ. Treatment of small cell lung cancer: surgery. En: Hansen HH (ed). Textbook of lung cancer. IASLC. Martin Dunitz. Londres 2000. Pg 243-250.

34- Donahue DM. Surgery for small-cell lung cancer. In Skarin AT (ed). Multimodality treatment of lung cancer. Marcel Dekker Inc. New York. 2000. Pg 337-349.

35- Hakim R. Surgery for small-cell lung cancer. In Skarin AT (ed). Multimodality treatment of lung cancer. Marcel Dekker Inc. New York. 2000. Pg 292-295.

35A- Fischer BM, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-45.

35B- Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129: 977-83.

35C- de Antonio DG, Alfageme F, Gamez P, et al; the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Results of surgery in small cell carcinoma of the lung. Lung Cancer 2006; 52: 299-304.

36- Chen LM, Lazcano O, Katzmann JA, et al. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998; 109: 712-721.

37- Shield PW, Perkins G, Wright RG. Immunocytochemical staining of cytologic specimens. How helpful is it? Am J Clin Pathol 1996; 105:157-162
Comentario en: Am J Clin Pathol. 1996; 105: 139-162

38- Motherby H, Friedrichs N, Kube M, et al. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology. Diagnostic accuracy in equivocal smears. Anal Cell Pathol 1999; 19: 59-66.

39- Ratto GB, Frola C, Sacco A, et al. The prognostic significance of minor pleural effusions in patients with potentially operable bronchogenic carcinoma. Lung Cancer 1987; 3: 117-122.

40- Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003; 40: 289-94.

41- Mitchell JD, Mathisen DJ, Wright CD, et al. Resection for bronchogenic carcinoma involving the carina: long-term results and effect of nodal status on outcome. J Thorac Cardiovasc Surg 2001; 121: 465-471.

41B- Herman SJ, Winton TL, Weisbrod GL, et al. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology 1994; 190: 841-6

41C- White PG, Adams H, Crane MD, et al. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours? Thorax 1994; 49: 951-957.
Comentario en: Thorax. 1994; 49: 941-943

Subir

41D- Bragg DG. The diagnosis and staging of primary lung cancer. Radiol Clin North Am 1994; 32: 1-14.

42- López Encuentra A (GCCB-S), Bülzebruck H, Feinstein AR, et al. Tumor staging and classification in lung cancer. Lung Cancer 2000; 29: 79-83.

43- Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical approach to patients presenting with multiple synchronous suspect lung lesions. A reflection on the current TNM classification based on 54 cases with complete follow-up. Lung Cancer 2001; 34: 169-175.

43B- Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002; 74: 988-93.

44- Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology 2004; 231: 164-8.

45- Morice RC, Peters EJ, Ryan MB, et al. Exercise testing in the evaluation of patients at high risk for complications from lung resection. Chest 1992; 101: 356-361.

45B- Brunelli A et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009;34:17-41.

45C- Ferguson MK, et al. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg 2008;85:1158-64.

45D- Brunelli A el al. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. Eur J Cardiothorac Surg 2006;29:567-70.

46- Reicher-Reiss H, Jonas M, Goldbourt U, et al. Selectively increased risk of cancer in men with coronary heart disease. Am J Cardiol 2001; 87: 459-462.

47- López Encuentra A, Salvatierra Velázquez A, Rami Porta R. Estadificación del Carcinoma Broncogénico. www.separ.es (Separ-FMC / Cursos)

47B- Baser S, Shannon VR, Eapen GA, et al. Pulmonary dysfunction as a major cause of inoperability among patients with non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 344-9.

48- López Encuentra A, Pozo Rodriguez F, Martín Escribano P, et al. Surgical lung cancer. Risk operative analysis. Lung Cancer 2004; 44: 327-37.

48B - López Encuentra A. Prediction of pulmonary function after lung resection. Current topics in General Thoracic Surgery. Vol 2. Elsevier, Amsterdam, 1992: 27-38.

48C- Kozower BD, et al. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg. 2010 ;90:875-81; discussion 881-3.

49- Moradiellos FJ, Martín de Nicólas JL, López Encuentra, et al. Mortalidad relacionada con la toracotomía en pacientes con carcinoma broncogénico y función pulmonar disminuida. Arch Bronconeumol 2001; 37: 65.

49B- Bryant AS et al.  The 30- versus 90-day operative mortality after pulmonary resection. Ann Thorac Surg 2010;89(6):1717-22.

50- Doddoli Ch, Barlesi F, Trousse D, et al. Risks of pneumonectomy: wich outcome measure?. ATS – 100th International Conference, May 21-26, 2004. Orlando. Florida. EEUU.

50B- Brunelli A, Rocco G. Internal validation of risk models in lung resection surgery: bootstrap versus training-and-test sampling. J Thorac Cardiovasc Surg 2006; 131: 1243-7.

51- Singh SJ, Morgan MD, Hardman AE, et al. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994; 7: 2016-2020.

Subir

52- Duque JL, Ramos G, Castrodeza J, et al and GCCB-S. Early complications and mortality in surgical treatment of bronchogenic carcinoma: A prospective multicenter study. Ann Thorac Surg 1997; 63: 944-950.

53- Rocmans PA. Surgical treatment of non-small cell lung cancer. Eur Respir Mon 2001; 17: 170-189.

54- Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.

55- Harpole DH Jr, DeCamp MM Jr, Daley J, et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. J Thorac Cardiovasc Surg 1999; 117: 969-79.

56- Beckles MA, Spiro SG, Colice GL, et al; American College of Chest Physicians. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123 (Suppl): 105S-114S.

56B- Win T, Jackson A, Groves AM, et al. Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. Thorax 2006; 61: 57-60.

56C- The European Thoracic Surgery Database project: modelling the risk of in-hospital death following lung resection. Eur J Cardiothorac Surg 2005; 28: 306-11.

56D- Varela-Simo G, et al; Sociedad Española de Neumologia y Cirugia Toracica. Guidelines for the evaluation of surgical risk in bronchogenic carcinoma. Arch Bronconeumol 2005; 41: 686-97.  

56E- Palange P, Ward SA, Carlsen KH, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007; 29: 185-209.

56F- van Tilburg PM et al.  Pre-operative pulmonary evaluation of lung cancer patients: a review of the literature. Eur Respir J. 2009;33:1206-15.

56G- Strand TE et al. Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude. Thorax 2007;62:991-7.

56H- Lim E, et al. Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe? Thorax 2010;65:847-9.

57- Wang J, Olak J, Ferguson MK. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg 1999; 117: 581-582.

58- Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989; 139: 902-910.
Comentario en: Am Rev Respir Dis 1989; 140: 1175-1176

59- Bernard A, Ferrand L, Hagry O, et al. Identification of prognostic factors determining risk groups for lung resection. Ann Thorac Surg 2000; 70: 1161-1167.

59B- Brunelli A et al. Risk-adjusted morbidity and mortality models to compare the performance of two units after major lung resections. J Thorac Cardiovasc Surg 2007;133:88-96.

59C- Kates M et al.. Validation of a model to predict perioperative mortality from lung cancer resection in the elderly. Am J Respir Crit Care Med 2009;179:390-5

59D- Falcoz PE et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007;133:325-32.

59E- Duque JL, et al. Risk factors in bronchogenic carcinoma surgery. Arch Bronconeumol 2007;43:143-9.

59F- Kim JB et al. Risk factor analysis for postoperative acute respiratory distress syndrome and early mortality after pneumonectomy: the predictive value of preoperative lung perfusion distribution. J Thorac Cardiovasc Surg 2010;140:26-31.

Subir

59FB- Falcoz PE, et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. J Thorac Cardiovasc Surg 2007;133: 325-32

59FC- Chamogeorgakis TP, et al. Thoracoscore predicts midterm mortality in patients undergoing thoracic surgery. J Thorac Cardiovasc Surg 2007;134: 883-7.

59G- Shaw AD el al. Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection. Ann Thorac Surg 2005; 79: 1704-10.

60- Auriant I, Jallot A, Herve P, et al. Noninvasive ventilation reduces mortality in acute respiratory failure following lung resection. Am J Respir Crit Care Med 2001; 164: 1231-5.

61- Díaz Cambriles T, López Encuentra A, Martin de Nicólas JL, et al. ¿Puede mejorar, o no modificarse, el FEV1 tras resección pulmonar por carcinoma broncogénico? Arch Broconeumol 2001; 37: 73-74.

61B- Brunelli A, Xiume F, Refai M, et al. Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis. Chest 2007; 131: 141-7.

61C- Kushibe K, Takahama M, Tojo T, et al. Assessment of pulmonary function after lobectomy for lung cancer--upper lobectomy might have the same effect as lung volume reduction surgery. Eur J Cardiothorac Surg 2006; 29: 886-90.

62- Korst RJ, Ginsberg RJ, Ailawadi M, et al. Lobectomy improves ventilatory function in selected patients with severe COPD. Ann Thorac Surg 1998; 66: 898-902

62B- Baldi S el al. Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study. J Thorac Cardiovasc Surg 2005;130:1616-22.

62C- Santambrogio L el al. Pulmonary lobectomy for lung cancer: a prospective study to compare patients with forced expiratory volume in 1 s more or less than 80% of predicted. Eur J Cardiothorac Surg 2001;20:684-7.

62D- Kashiwabara K el al. Relationship between functional preservation after segmentectomy and volume-reduction effects after lobectomy in stage I non-small cell lung cancer patients with emphysema. J Thorac Oncol 2009;4:1111-6.

63- Díaz-Cambriles T, López Encuentra A, Martín de Nicolas JL et al. Could the FEV1 improve after surgery for lung cancer ?. Am J Respir Crir Care Med 2004: 169 (sup 1): A336.

63B- Vaughan P, et al. Is there a role for therapeutic lobectomy for emphysema? Eur J Cardiothorac Surg 2007;31:486-90.

63C- Martin-Ucar AE, Khaleel FR, Nakas A, Vaughan P, Edwards JG, Waller DA. Is the initial feasibility of lobectomy for stage I non- small cell lung cancer in severe heterogeneous emphysema justified by long-term survival? Thorax 2007 Feb 8; [Epub ahead of print]

64- Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-73.

65- Choong CK, Meyers BF, Battafarano RJ, et al. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J Thorac Cardiovasc Surg 2004; 127: 1323-31.

66- Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615-622. Comentario en: Ann Thorac Surg. 1996; 62: 1249-1250

66B- Yang M, et al. Does a Protective Ventilation Strategy Reduces the Risk of Pulmonary Complications Following Lung Cancer Surgery?: a Randomized Controlled Trial. Chest.2010 Sep 9. [Epub ahead of print]

67- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-1049
Comentario en: ACP Journal Club, march/april 2000

68- Gilbert K, Larocque BJ, Patrick LT. Prospective evaluation of cardiac risk indices for patients undergoing noncardiac surgery. Ann Inter Med 2000; 133: 356-3<59.
Comentario en: Ann Intern Med 2000; 133: 384-386

Subir

68B- Karthikeyan G, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009 Oct 20;54(17):1599-606.

69-ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105: 1257-1267.

70- Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345: 1677-82.

71- Grayburn PA, Hillis LD. Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. Ann Intern Med 2003; 138: 506-11.

72- Frost SD, Michota FA. Risk stratification for noncardiac surgery. Ann Intern Med 2004; 140:

72B- ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;116:1971-96.

72C- Bangalore S. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008;372:1962-76

73- Fernández-Miranda C, Aranda JL, Paz M, et al. Aterosclerosis subclínica de la arteria carótida en pacientes con enfermedad coronaria. Med Clin (Barc) 2001; 116: 441-445.

74- Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 2001; 161: 1669-1676.

75- Alamowitch S, Eliasziw M, Algra A, et al, for the North American Symptomatic Carotid Endarterectomy Trial Group. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001; 357: 1154-1160.
Comentario en: Lancet. 2001; 357:1142-1143

76- Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123 (1 Suppl): 137S-146S.

76B- Vansteenkiste J, Fischer BM, Dooms C, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-40.

76C- Herder GJ, Kramer H, Hoekstra OS, et al; POORT Study Group.Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-6.

77- Herman SJ, Winton TL, Weisbrod GL, et al. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology 1994; 190: 841-6

78- White PG, Adams H, Crane MD, et al. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliably identify stage III tumours? Thorax 1994; 49: 951-957.
Comentario en: Thorax. 1994; 49: 941-943

79- Bragg DG. The diagnosis and staging of primary lung cancer. Radiol Clin North Am 1994; 32: 1-14.

80- Márquez Pérez FL, Martínez Cruz R, López Encuentra A, et al. Valor de los datos clínicos en la predicción de metástasis óseas estudiadas por rastreo óseo isotópico en el carcinoma broncogénico. Archiv Bronconeumol 1993; 29: 320-323

81- Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991; 46: 469-473

82- Guyatt GH, Cook DJ, Griffith LE, et al. Surgeons' assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer. Canadian Lung Oncology Group. Ann Thorac Surg 1999; 68: 309-315

83- Millán Juncos JM, Escudero Pérez L, López Roger R, et al. Utilidad de la tomografía computarizada cerebral en la detección de metástasis cerebrales de carcinoma de pulmón neurológicamente asintomáticas. An Med Intern (Madrid) 1984; 1: 127-131

Subir

84- Cole FH Jr, Thomas JE, Wilcox AB, et al. Cerebral imaging in the asymptomatic preoperative bronchogenic carcinoma patient: is it worthwhile? Ann Thorac Surg 1994; 57: 838-840

85- Colice GL, Birkmeyer JD, Black WC, et al. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995; 108: 1264-1271.

86- Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.

87- Margolis ML. Does a positive brain CT reflect brain metastases? Chest 1995; 108: 295-6.

88- Silvestri GA, Tanoue LT, Margolis ML, et al; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003 ;123 (1 Suppl): 147S-156S.

89- Alvarez Martínez C, Sánchez Nistal A, Arenas de Pablo A, et al. Detección de metástasis hepáticas y suprarrenales en el carcinoma broncogénico mediante tomografía axial computarizada. Arch Bronconeumol 1990; 26 (sup): 67

90- Eggesbo HB, Hansen G. Clinical impact of adrenal expansive lesions in bronchial carcinoma. Acta Radiol 1996; 37: 343-347.

91- Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest 1992; 102: 1748-1751.
Comentario en: Chest 1994;105: 1626-1627

92 - Burt M, Heelan RT, Coit D, et al. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg 1994; 107: 584-589.
Comentario en: J Thorac Cardiovasc Surg 1995; 109: 814-815

93- Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995; 197: 411-418.

94- Heinz-Peer G, Honigschnabl S, Schneider B, et al. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR 1999; 173: 15-22.
Comentario en: AJR Am J Roentgenol. 1999; 173:23-24

95- Hellwig D, Ukena D, Paulsen F, et al. Metaanalysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose. Pneumologie 2001; 55: 367-377

96- Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR 1999; 173: 25-29.

97- Zubeldia J, Abou-Zied M, Nabi H. Patterns of adrenal gland involvement from lung cancer shown by 18F-Fluorodeoxyglucose positron emission tomography compared to computed tomography and magnetic resonance imaging. Clin Positron Imaging 2000; 3: 166.

98- Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97: 1052-1058.

99- Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med 1995; 152: 225-30

100 - Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49: 14-9
Comentario en: Thorax 1994; 49: 1-2

101- Goldstraw P, Bureau G, Cullen M, et al. Pretreatment minimal staging for non-small cell lung cancers: a consensus report. Lung Cancer 1991; 7: 7-9

102- Tanaka K, Kubota K, Kodama T, et al. Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T1-2 N0. Ann Thorac Surg 1999; 68: 1039-1042.

103- National Health Service. UK. Improving outcomes in lung cancer. The research evidence. Guidance on Commissioning Cancer Services. NHS executive. 1998.

Subir

104- Hochstenbag MM, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 2003; 42: 189-93.

104B- Sánchez de Cos Escuín J. Metástasis encefálicas silentes en la estadificación inicial del cáncer de pulmón. Evaluación mediante tomografía computarizada y resonancia magnética. Arch Bronconeumol 2007;43:386-91.

105- The Canadian Lung Oncology Group. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. Ann Thorac Surg 2001; 71: 425-433

106- Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. New Eng J Med 2000; 343: 254-261.
Comentario en: N Engl J Med. 2000; 343: 290-292

107- Vansteenkiste JF, Stroobants SG. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J 2001; 17: 802-820.

108- Kalff V V, Hicks RJ, P MacManus M, et al. Clinical impact of (18)F-fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study. J Clin Oncol 2001; 19: 111-118

108B- Fischer B, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.

108C- Ung YC, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. Natl Cancer Inst 2007;99:1753-67

108D- Maziak DE, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med.2009;151:221-8.

108E- Lardinois D et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 2005;23:6846-53.

108F- Navani N, et al. EBUS-TBNA for the mediastinal staging of non-small cell lung cancer. J Thorac Oncol 2009;4:776; author reply 776-7.

108G- De Wever W, et al. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009;33:201-12.

109- Pfister DG, Johnson DH, Azzoli CG, et al; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-53.

109B- Pozo-Rodríguez F. La PET y  la estadificación del carcinoma broncogénico.  Otro ensayo clínico para diagnóstico. www.mbeneumologia.org

110- Stroobants SG, D'Hoore I, Dooms C, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer 2003; 4: 242-7.

110B- Viney RC, Boyer MJ, King MT, et al. Randomized Controlled Trial of the Role of Positron Emission Tomography in the Management of Stage I and II Non-Small-Cell Lung Cancer. J Clin Oncol 2004: 15: 2357-62.

110C- Pozo-Rodríguez F. La PET y la Estadificación del Carcinoma Broncogénico. Otro ensayo clínico para diagnóstico. www.mbeneumologia.org

110D- Solis Ruiz S. Algoritmo Diagnóstico del CPNCP com PET-TC. 2010 (basado en Rev Esp Med Nucl 2009; 28:167-72)

112- Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. A commentary. J Thorac Cardiovasc Surg 1990; 99: 48-53.

113- Martín de Nicólas Serrahima JL, García Barajas S, Marrón Fernández C, et al. Complicaciones técnicas de la exploración quirúrgica del mediastino en la estadificación del cáncer de pulmón. Arch Bronconeumol 1999; 35:390-394.

Subir

114- Hammoud ZT, Anderson RC, Meyers BF, et al. The current role of mediastinoscopy in the evaluation of thoracic disease. J Thorac Cardiovasc Surg 1999; 118: 894-899.

114B-   De Leyn P, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines.  J Thorac Oncol 2007;2:357-61.

114C- Detterbeck F, et al. Classification of the thoroughness of mediastinal staging of lung cancer. Chest 2010;137:436-42.

114D- Rami Pota R, et al. En Tratado de Cirugía Torácica. Fernández Fau L, Freixinet Gilart J (eds). SEPAR. EDIMSA. 2010; pg: 889-907.

114E- Darling GE, et al. Number of Lymph Nodes Harvested from a Mediastinal Lymphadenectomy: Results of the Randomized, Prospective ACOSOG Z0030 Trial. Chest 2010 Sep 9. [Epub ahead of print]

115- Pozo Rodríguez F, Sánchez Nistal MA, Maldonado Suarez A, et al. Tomografía de emisión de positrones y TC helicoidal en la estadificación ganglionar mediastínica del Carcinoma Broncogénico. Arch Bronconeumol 2004; 40 (sup 2): 88-9

116- Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004; 44: 175-81.

117- Martín de Nicolás Serrahima JL, Sánchez Nistal A, Varela Simo G, et al. Correlación CT-Mediastinoscopia en la extensión ganglionar del carcinoma broncogénico. Estudio prospectivo. Arch Bronconeumol 1989; 25 (Sup): 52.

118- Cerfolio RJ, Ojha B, Bryant AS, et al. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003; 76: 861-6.

119- Keller SM, Vangel MG, Wagner H, et al; Eastern Cooperative Oncology Group. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
J Thorac Cardiovasc Surg 2004; 128: 130-7.

119B- Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
J Thorac Cardiovasc Surg 2006; 131: 822-9.

120- Reed CE, Harpole DH, Posther KE, et al; American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1943-51.

121- Kernstine KH. Positron emission tomography with 2-[18f]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy? J Thorac Cardiovasc Surg 2003; 126: 1700-3.

122- De Leyn P, Vansteenkiste J, Cuypers P, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg 1997; 12: 706-12.

122B- Sayas J, et al. Clinical value of 18-FDG PET-CT in mediastinal lymph node staging in non-small cell lung cancer (NSCLC) patients with previous cN0-1 on CT. Eur Resp J 2007;30:665s

122C- Serra M, et al. Routine PET and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer. J Clin Oncol 2006;24;suppl:18s.

123- Akhurst T, Heelan R. Imaging work-up of lung cancer: utility and comparison of computed tomography and FDG positron emission tomography. In: Ginsberg DJ. Lung Cancer. American Cancer Society. Atlas of Clinical Oncology. Decker. Hamilton. 2002: 71-94

124- van Tinteren H, Hoekstra OS, Smit EF, et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002; 359: 1388-93.

125- Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18: 2981-2989.

126- Suzuki K, Nagai K, Yoshida J, et al. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 1999; 118: 145-153

Subir

127- De Leyn P, Vansteenkiste J, Deneffe G, et al. Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. Eur J Cardiothorac Surg 1999; 15: 608-614.

128- Ichinose Y, Kato H, Koike T, et al. The Japan Clinical Oncology Group. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of The Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001; 34: 29-36.

128B- Al-Sarraf N, et al.  Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.  Eur J Cardiothorac Surg 2008;33:104-9.

129- Vesselle H, Pugsley JM, Vallieres E, Wood DE. The impact of fluorodeoxyglucose F 18 pos

130- Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, D'Amico TA. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1900-5.

131- Kernstine KH, McLaughlin KA, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002; 73: 394-401.

132- Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-536.

133- Laking G, Price P. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer. Thorax. 2001; 56 Suppl 2: ii38-44.

134- Kelly RF, Tran T, Holmstrom A, et al. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Chest 2004; 125: 1413-23.

135- Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998; 66: 1876-83.

135B- Serra Mitjans M, Rami Porta R, Belda Sanchis J et al. Preliminary results of a change in clinical staging protocol for NSCLC: Routine versus selective mediastinoscopy based on PET scan. Lung Cancer 2005; 49 (supp 2): S27

136- Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-92.

137- Mateu M, García Domingo MI, Villanueva MJ, et al. Staging value of left parasternal mediastinotomy in left lung cancers. Procc. The 8th European Conference on General Thoracic Surgery. 1st - 3rd November 2000. London. UK.

138- Annema JT, Veselic M, Versteegh MI, et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 2003; 42: 311-8.

139- Soria MT, Gines A, Belda J, et al. Usefulness of endoscopic ultrasound-guided fine needle aspiration (EUS-G FNA) in diagnosing the extension of non-small cell lung cancer. Arch Bronconeumol 2002; 38: 536-41.

140- Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg 2004; 77: 1763-8.

141- Kramer H, van Putten JW, Post WJ, et al. Oesophageal endoscopic ultrasound with fine needle aspiration improves and simplifies the staging of lung cancer. Thorax 2004; 59: 596-601.

142- Kramer H, Groen HJ. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg 2003; 238: 180-8.

143- Annema JT, Hoekstra OS, Smit EF, et al. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer 2004; 44: 53-60.

144- Toloza EM, Harpole L, Detterbeck F, et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123 (1 Suppl): 157S-166S.

Subir

144B- Annema JT, et al. State of the art lecture: EUS and EBUS in pulmonary medicine. Endoscopy 2006;38 Suppl 1:S118-22.

144C- Annema JT, et al. Why respiratory physicians should learn and implement EUS-FNA. Am J Respir Crit Care Med 2007;176:99; author reply 99.

144D- Janes SM, et al. Esophageal endoscopic ultrasound/endobronchial ultrasound-guided fine needle aspiration: a new dawn for the respiratory physician? Am J Respir Crit Care Med 2007;175:297-9.

144E- Herth FJ, et al. Combined Endoesophageal-Endobronchial Ultrasound-Guided, Fine-Needle Aspiration of Mediastinal Lymph Nodes through a Single Bronchoscope in 150 Patients with Suspected Lung Cancer. Chest 2010 Feb 12. [Epub ahead of print])

144F- Hwangbo B, et al. Transbronchial and Transesophageal Fine Needle Aspiration Using an Ultrasound Bronchoscope in Mediastinal Staging of Potentially Operable Lung Cancer. Chest 2010 Mar 26. [Epub ahead of print])

144G- Gottlieb K, et al. Lung cancer staging by endoscopic and endobronchial ultrasound-guided fine-needle-aspiration. Arch Bronconeumol 2009;45:603-10.

144H- Wallace MB, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008; 299: 540-6

144J- Steinfort DP, et al. Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis. J Thorac Oncol 2010 ;5:1564-70.

145- Detterbeck FC, DeCamp MM Jr, Kohman LJ, et al; American College of Chest Physicians. Lung cancer. Invasive staging: the guidelines. Chest 2003; 123 (1 Suppl): 167S-175S.

145B- Al-Sarraf N, et al. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer 2008;60: 62-8.

145C- Lardinois D, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003 Jun 19;348(25):2500-7.

145D- Cerfolio RJ, et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23.

146- Sebastian-Quetglas F, Molins L, Baldo X, et al; Spanish Video-assisted Thoracic Surgery Study Group. Clinical value of video-assisted thoracoscopy for preoperative staging of non-small cell lung cancer. A prospective study of 105 patients. Lung Cancer 2003; 42: 297-301.

146B- De Leyn P, Lardinois D, Van Schil P, et al. Preoperative lymph node staging for non-small cell lung cancer. ESTS guidelines. www.ests.org (accesible en enero 2007). Eur J Cardio-thorac Surg 2007; 32:1-8.

146C- de Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006; 29: 26-9.

146D- Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG.Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. Chest 2007; 131: 539-48.

146E- Varela-Lema L, et al. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J 2009;33:1156-64.

146F- Gu P, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 2009;45:1389-96.

146G- Adams K, et al. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 2009;64:757-62.

146H- Cerfolio RJ, et al. The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with non-small cell lung cancer. Ann Thorac Surg 2010;90:427-34.

Subir

146K- Tournoy-KG, et al. A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer. J Clin Oncol 28:15s, 2010; suppl; abst 7000.

146L- Kemp SV, et al. Learning curves for endobronchial ultrasound using cusum analysis. Thorax 2010;65:534-8.

146M- Block MI, et al. Endobronchial ultrasound for lung cancer staging: how many stations should be sampled? Ann Thorac Surg 2010;89:1582-7.

146N- Diacon AH, et al. Rapid on-site evaluation of transbronchial aspirates: randomised comparison of two methods. Eur Respir J 2010;35:1216-20.

146P- Association of Directors of Anatomic and Surgical Pathology.  Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Am J Clin Pathol. 2001;115:799-801.

146R- Garcia-Olivé I, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010;35:391-5.

146RB- Sakairi Y, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010; 16: 4938-45.

146RC- Schuurbiers OCJ, et al. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010;5:1664-7.

146S- Fujiwara T, et al. The utility of sonographic features during EBUS-TBNA for lymph node staging in patients with lung cancer - A Standard EBUS Image Classification System. Chest 2010 Apr 9. [Epub ahead of print]).

147- Gomez Caro A, Gigirey O, Marrón C, et al. Cambio de estadificación clínica por mediastinotomía anterior en carcinoma broncogénico del lóbulo superior izquierdo por invasión local. Arch Bronconeumol 2004; 40 (S2): 72.

148- Grupo de Trabajo de la SEPAR. Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico. Arch Bronconeumol 1998; 34: 437-452.

149- GCCB-S. Estadificación ganglionar intraoperatoria en la cirugía del carcinoma broncogénico. Documento de consenso. Arch Bronconeumol 2001; 37: 495-503.

149B- Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006; 30: 787-92.

149C- Association of Directors of Anatomic and Surgical Pathology. Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Am J Clin Pathol 2001; 115: 799-801. 

150- Pozo Rodríguez F. Linfadenectomía radical mediastínica en el CBNM.  www.mbeneumologia.org.

151- Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-92.

151B- Conron M, Phuah S, Steinfort D, et al.Analysis of multidisciplinary lung cancer practice. Intern Med J 2007; 37: 18-25.

152- Gómez de la Cámara A. variabilidad en el tratamiento del cáncer de pulmón y supervivencia. www.mbeneumologia.org

152B- Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006; 130: 1211-9.

153- Coulter A. Patient information and shared decision-making in cancer care. Br J Cancer 2003;89 (Suppl 1): S15-6.

Subir

154- GCCB-S. Clinical tumor size and prognosis in lung cancer. Eur Respir J 1999; 14: 812-816.

155- Rami Porta R, and GCCB-S. Reflections on the Revisions in the International System for Staging Lung Cancer. Chest 1998; 113: 1728-1729.

156- Bronchogenic Carcinoma Co-operative Group of the Spanish Society of Pneumology and Thoracic Surgery (GGCB-S). Survival of 2,991 patients with surgical lung cancer: the denominator effect in survival. Chest 2005; 128: 2274-81.

156B-  Duque JL, et al. Risk factors in bronchogenic carcinoma surgery. Arch Bronconeumol 2007;43:143-9.

156C- Grutters JPC, et al. Health-related quality of life in patients surviving non-small cell lung cancer. Thorax 2010; 65: 903-7.

157- Brundage MD, Feldman-Stewart D. Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2001; 19: 1326-1335.

158- Dowie J, Wildman M. Choosing the surgical mortality threshold for high risk patients with stage Ia non-small cell lung cancer: insights from decision analysis. Thorax 2002; 57: 7-10.

159- López Encuentra A, Martin de Nicolas JL, Casado Lopez M, et al, and GCCB-S. Demora en el diagnóstico y en el tratamiento quirúrgico del carcinoma broncogénico. Arch Bronconeumol 1998; 34; 123-126.

160- Aragoneses FG, Moreno N, León D, et al, and GCCB.S. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002; 36: 59-63.

161- Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer?. A retrospective analysis from a single UK centre. Lung Cancer 2001; 34: 243-252.

162- Saunders M, Sculier JP, Ball D, et al. Consensus: the follow-up of the treated patient. Lung Cancer. 2003;42 (Suppl 1): S17-9.

162B- Parsons A, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010 Jan 21;340:b5569. doi: 10.1136/bmj.b5569.

163- Macbeth F, Toy E, Coles B, et al. Palliative radiotherapy regimens for non-small cell lung cancer (Cochrane Review). Cochrane Database Syst Rev 2001;2:CD002143

164- Toy E, Macbeth F, Coles B, et al. Palliative thoracic radiotherapy for non-small-cell lung cancer: a systematic review. Am J Clin Oncol 2003; 26: 112-20.

165- Falk SJ, Girling DJ, White RJ, et al; Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 2002; 325: 465.

166- Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 2003; 4: 120-8.

167- Villena V, Lopez Encuentra A, Pozo F, et al. Measurement of pleural pressure during therapeutic thoracentesis. Am J Respir Crit Care Med 2000; 162; 1534-1538.

168- Kvale PA, Simoff M, Prakash UB; American College of Chest Physicians. Lung cancer. Palliative care. Chest 2003; 123 (1 Suppl): 284S-311S.

169- Silvestri GA, Sherman C, Williams T, et al. Caring for the dying patient with lung cancer. Chest 2002; 122: 1028-36.

169B- Vergnon JM, Huber RM, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J 2006; 28: 200-18.

Subir

169C- Temel JS, et al. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer. N Engl J Med 2010;363:733-742.

169D- Rami-Porta R, et al. Sublobar resection for lung cancer. Eur Respir J 2009;33:426-35.

169DD- Blasberg JD, et al. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol 2010; 5:1583-93.

169E- Stiles BM, et al. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 2009;137:13-9.

169F- Detterbeck FC. Sublobar resection: are the answers different or is it the questions? J Thorac Oncol 2010; 5:1500-1.

170- Deslauriers J, Gregoire J, Jacques LF, et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004; 77: 1152-6.

170B- Rami-Porta R, Wittekind C, Goldstraw P; International Association for the Study of Lung Cancer (IASLC) Staging Committee.Complete resection in lung cancer surgery: proposed definition.
Lung Cancer 2005; 49: 25-33. 

170C- Rami-Porta R, Mateu-Navarro M, Freixinet J, et al; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).Type of resection and prognosis in lung cancer. Experience of a multicentre study. Eur J Cardiothorac Surg 2005; 28: 622-8.

170D- Massard G, Ducrocq X, Kochetkova EA, et al. Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg 2006; 30: 164-7.

170E- Wright G, Manser RL, Byrnes G, et al. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006; 61: 597-603.

170F- Allen MS, Darling GE, Pechet TT, et al; ACOSOG Z0030 Study Group.Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006; 81: 1013-9.

170G- Watanabe S, et al. Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol 2009;4:652-7.

170H- Darling GE, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma. ACOSOG Z0030 trial. J Thorac Cardiovasc Surg 2010, en prensa.

170L- Ishiguro F et al. Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg 2010;139:1001-6

170M- Tamura M, et al. Current treatment paradigms of superior sulcus tumours. Eur J Cardiothorac Surg 2009; 36:747-53.

170N- Travis WD. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009; 54:3-11.

171- Dartevelle PG, Chapelier AR, Macchiarini P, et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic i
Comentario en: J Thorac Cardiovasc Surg 1994; 108: 389-392 . J Thorac Cardiovasc Surg 1996; 112: 558-560

172- Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg 1998; 66: 193-198.
Comentario en: Ann Thorac Surg. 1998; 66: 2160-2161

173- Rusch VW, Parekh KR, Leon L, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg 2000; 119: 1147-1153.

174- Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472-483.

Subir

175- Detterbeck FC, Jones DR, Kernstine KH, et al; American College of Physicians. Lung cancer. Special treatment issues. Chest. 2003; 123 (1 Suppl): 244S-258S.

176-  Wright CD, Menard MT, Wain JC, et al. Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. Ann Thorac Surg  2002; 73: 1541-4.

177- Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25: 313-8.

177B- Marra A, Eberhardt W, Pottgen C, et al. Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. Eur Respir J 2007; 29: 117-26. 

177C- Detterbeck F, et al. What to do with "Surprise" N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008;3:289-302.

178- PORT meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352: 257-263.
Comentarios en: Lancet 1998; 352: 250-251. Lancet 1998;352: 1384-5; discussion 1385-6

178B- Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24: 2998-3006. 

178C- Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, Green MR. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Clin Lung Cancer 2007; 8: 268-72.

178D- Douillard JY, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.  Int J Radiat Oncol Biol Phys 2008;72:695-701.

178E- Crinò L, et al.  ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v103-15.

178F- NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77.  

178G- Arriagada R, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42.

178H- Butts CA, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.

178J- Felip E, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer . J Clin Oncol 2010;28:3138-45

179- Okawara G, Ung YC, Markman BR, et al; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2004; 44: 1-11.

180- Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Eng J Med 2000; 343: 1217-1222.
Comentario en: N Engl J Med 2000; 343: 1261-1262

181- Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-82.

182- Scagliotti GV, Fossati R, Torri V, et al; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95: 1453-61.

183- Kato H, Ichinose Y, Ohta M, et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.

184- Arriagada R, Bergman B, Dunant A, et al; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.

Subir

185- Strauss GM, Nerndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with placlitaxel and carboplatin following resection in sage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Abstract # 7019. Proced. ASCO Annual Meeting 2004. www.asco.org

185B- Bria E, et al Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009;63:50-7.

186- Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.

186B- Strauss GM, Nerndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with placlitaxel and carboplatin following resection in sage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Abstract # 7007. Proced. ASCO Annual Meeting 2006. www.asco.org

186C- Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 2006; 8: 18-21.

186D- Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.

186E- Strauss GM, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.

187- Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3860-7.

187B- Hotta K, Matsuo K, Kiura K, et al. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Curr Opin Oncol 2006; 18: 144-50. 

187C- Pepe C, Hasan B, Winton T et al. National Cancer Institute of Canada Clinical Trials. Adjuvant chemotherapy in elderly patientes: An analysis of  National Cancer Institute of Canada Clinical Trials Group and Intergroup JBR.10. J Clin Oncol 2007;25:1553-61.

187D- Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. Int J Cancer 2006; 119: 955-60.

187E- Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.

187F- Früh M, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008;26:3573-81.

188- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15.

189- International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.

190- Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.
BMJ 1998; 317: 771-5.

190B- Silvestri G. Chemotherapy for advanced lung cancer: is the glass half full or half empty?
Thorax 2004; 59: 821.

190C- Paull DE, Thomas ML, Meade GE, et al. Determinants of quality of life in patients following pulmonary resection for lung cancer. Am J Surg 2006; 192: 565-71.

190D- Bezjak A , et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008;26:5052-9.

190E- Wisnivesky JP, et al. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010;181:264-9

Subir

191- Sibley GS. Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma: smaller volumes and higher doses--a review. Cancer 1998; 82: 433-438.

192- Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer 1994; 11: 153-178.

193- Robertson JM, Ten-Haken RK, Hazuka MB et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1079-1085

194- Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable) (Cochrane Review). In: The Cochrane Library, issue 4, 2003. Oxford: Update Software.

195- Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001; 56: 628-638.

196- Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001; 32: 71-79.

197- Amstrong J, Gibney LM. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. Radiotherapy and Oncology 2000; 56: 157-167

198- Touboul E, Lagrange JL, Theobald S, et al. Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traites par irradiation exclusive. Cancer Radiother 2001; 5: 452-463.

199- Price A. Lung cancer 5: state of the art radiotherapy for lung cancer. Thorax 2003; 58: 447-52.

200- Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 119-130.

201- Qiao X, Tullgren O, Lax I, et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003; 41: 1-11.

201B- Fang LC, Komaki R, Allen P, et al. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 108-16.

201C- San Jose S, Arnaiz MD, Lucas A, et al. Radiation therapy alone in elderly with early stage non-small cell lung cancer. Lung Cancer 2006; 52: 149-54.

201D- Crabtree TD, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer J Thorac Cardiovasc Surg 2010;140:377-86.

201E- Grills IS, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010;28:928-35.

201F- Altorki NK, et al . Stereotactic body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all? J Clin Oncol;28:905-7.

201G- Timmerman R, et al. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: who's down for the count? J Clin Oncol 2010;28:907-9.

201H- Onishi H, et al. Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys 2010 Jul 15. [Epub ahead of print]

201J- Lanni TB, et al. Stereotactic Radiotherapy Reduces Treatment Cost While Improving Overall Survival and Local Control Over Standard Fractionated Radiation Therapy for Medically Inoperable Non-Small-Cell Lung Cancer. Am J Clin Oncol 2010 Aug 27. [Epub ahead of print]

201K- De Ruysscher D, et al. European Organization for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer.J Clin Oncol. 2010 Nov 15. [Epub ahead of print]

Subir

201L- Timmerman R. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-6.

202- Ashare A, Carroll J. Changes in airflow following primary external beam radiation therapy for non-small cell lung carcinoma. AJRCCM 2004; 169 (sup 1): A340

203- Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Eng J Med 1994; 330: 153-8.
Comentarios en: N Engl J Med. 1994; 330: 206-207. N Engl J Med. 1994;330: 1756; discussion 1757

204- Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
Comentario en: J Natl Cancer Inst. 1994; 86: 650-651

205- Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7-14
Comentario en: Lung Cancer 2000; 28: 247-251.

206- Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
Comentario en: Lung Cancer 2000; 28: 247-251

207- Ichinose Y, Tsuchiya R, Kato H, et al. The Japan Clinical Oncology Group - Lung Cancer Surgical Study Group 9209. Randomized trial of chemotherapy followed by surgery for stage IIIA N2 non-small cell lung cancer. Lung Cancer 2000; 29 (sup 2): 173

209- Detterbeck FC, Jones DR. Surgical treatment of stage IIIa (N2) non-small cell lung cancer.  In: Detterbeck FC, Rivera MP, Socinski MA (Eds). Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia. PA. WB Saunders. 2001: 267-282.

210- Radiation Therapy Oncology Group (RTOG) 9309. A phase III comparison between concurrent chemotherapy plus radiotherapy, and concurrent chemotherapy plus radiotherapy followed by surgical resection for stage IIIA (N2) non-small cell lung cancer.
www.rtog.org/members/protocols/93-09/12/16/2000

210-b - Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 1998; 19: 3-13.

211- Inoue M, Sawabata N, Takeda S, et al. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg 2004; 127: 1100-6.

212- Vansteenkiste JF, De Leyn PR, Deneffe GJ, ET AL. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63: 1441-50.

213- Warren WH. Surgery for potentially / marginally resectable pathological N2-NSCLC: Pro. In Movsas B (ed). Controversies in lung cancer. A multidisciplinary approach. Mercel Dekker. New York. 2001; 187-212.

214- Gore EM, Byhardt RW. Surgery for potentially / marginally resectable pathological N2-NSCLC: Con. Movsas B (ed). Controversies in lung cancer. A multidisciplinary approach. Mercel Dekker. New York. 2001; 213-224.

215- van Overhagen H, Brakel K, Heijenbrok MW, et al. Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. Radiology 2004; 232: 75-80.

216- Ohno K, Utsumi T, Sasaki Y, et al. Re-evaluation of non-palpable scalene lymph node biopsy for the staging of non-small cell lung cancer. Eur J Cardiothorac Surg 2004; 25: 492-6.

217- Caras WE. Postpneumonectomy pulmonary edema: can it be predicted preoperatively?. Chest 1998; 114: 928-931.

218- Leo F, Solli P, Spaggiari L, et al. Respiratory function changes after chemotherapy: an additiona

218B- Lopez-Encuentra A, Martin de Nicolas JL, Paz-Ares L, Bartolome A; Grupo Cooperativo de Carcinoma Broncogenico del Hospital Universitario 12 de Octubre de Madrid. Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma. What is the answer? Arch Bronconeumol 2006; 42: 154. Reply: Arch Bronconeumol 2007 (en prensa).

218C- Betticher DC, Hsu Schmitz SF, Totsch M, et al; Swiss Group for Clinical Cancer Research (SAKK).Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94: 1099-106.

Subir

218D- Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1033-40.

218E- Takeda S, Funakoshi Y, Kadota Y, et al. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? Ann Thorac Surg 2006; 82: 232-6.

218F- Doddoli C, Barlesi F, Trousse D, et al.One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005; 130: 416-25.

219- Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M, Hernandez-Rodriguez H. Remediastinoscopy: comments and updated results. Lung Cancer 2003; 42: 363-4.

220- Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000; 70: 391-5.

221- Van Schil P, van der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer 2002; 37: 281-5.

222 - Mateu Navarro M, Rami Porta R, Serra Mitjans M. Preliminary survival analisis of patients with non-small cell lung cancer after induction therapy followed by surgical restaging and lung resection or palliative treatment. Lung Cancer 2003; 41 (Supp 2): 190.

223- Rami Porta R. Restaging after induction therapy for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2002; 8: 325-7.

224- Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21: 1752-9.

225- Lardinois D, Schallberger A, Betticher D, at al. Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg 2003; 75: 1102-6.

225B- De Waele M, et al. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg 2006;29:240-3.

225C- Marra A, et al. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg 2008;135:843-9.

225D- De Waele M, et al. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg 2008;33:824-8.

225E- Call S, et al. Joint International Symposium on Thoracic Surgery. Barcelona. 25-27 noviembre 2009

225F- Call S, et al. Interact CardioVasc Thorac Surg 2010;11:1-58s

225G- Lardinois D, et al.  Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg 2003;75:1102-6.

226- Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-40.

227- Vansteenkiste J, Stroobants S, Hoekstra C, et al. 18-fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: a multicenter prospective study. Proc Am Soc Clin Oncol 2001; 20: A313.

227B- Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125: 2300-8. 

227C- Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004; 77: 254-9.

Subir

227D- Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006; 131: 1229-35.

227E- Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128: 892-9.

227EB- Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.

227EC- Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507. 

227F- Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 8362-70.

227FA- Vansteenkiste J, Dooms C.Positron emission tomography in nonsmall cell lung cancer. Curr Opin Oncol 2007; 19: 78-83.

227G- De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24: 3333-9.

227H- De Waele M, Hendriks J, Lauwers P, et al.Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg 2006; 29: 240-3.

227I- Granone P, Van Schil P, Cesario A. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a closer look at redo mediastinoscopy. J Thorac Cardiovasc Surg 2007; 133: 275-6; author reply 276-7. 

227K- de Cabanyes Candela S, et al. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010;5:389-98.

227L- Cerfolio RJ, et al. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008;86:912-20; discussion 912-20.

227M- Szlubowski A, et al. Endobronchial ultrasound-guided needle aspiration in non-small-cell lung cancer restaging verified by the transcervical bilateral extended mediastinal lymphadenectomy--a prospective study. Eur J Cardiothorac Surg 2010;37:1180-4.

227N- Bruzzi JF, et al. PET/CT imaging of lung cancer. J Thorac Imaging 2006 May;21(2):123-36.

228- Nagai K, Tsuchiya R, Mori T, et al; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125: 254-60.

229- Depierre A, Milleron B, Moro-Sibilot D, et al; French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-53.

230- López Encuentra A, Gómez de la Cámara A. Quimioterapia neoadyuvante en cirugía en carcinoma broncogénico no microcítico, estadios IB a IIIA. www.mbeneumologia.org

231- Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 2004; 58: 204-12.

232- Albain KS. Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA (N2) non-small cell lung cancer (NSCLC): First outcome analysis of North American Intergroup trial 0139 (RTOG 93-09). Lung Cancer 2003; 41 (Supp 2): 4.

233- Turrisi AT, Scott CB, Rusch VR, et al. Randomized trial of chemotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309). Int J Radiat Oncol Biol Phys 2003; 57 (suppl 2): 125-6s.

233B- van Meerbeeck JP, Kramer G, Van Schil PE, et al; EORTC-Lung Cancer Group. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol 2005; 23 (16s): 1095S

Subir

233C- Lagakos SW. The challenge of subgroup analyses--reporting without distorting. N Engl J Med 2006; 354: 1667-9.

233D- Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 2006; 354: 1744-6. 

233DB- Barraclough H et al. Biostatistics primer: what a clinician ought to know: subgroup analyses. J Thorac Oncol 2010; 5: 741-6.

233E- Albain KS, et al Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.

233F- van Meerbeeck JP, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 2007;99:442-50.

233G- Robinson LA, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132 (3 Suppl):243S-265S.

233H- Thomas M, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008;9:636-48.

234- Hubaut JJ, Baron O, Al Habash O, et al. Closure of the bronchial stump by manual suture and incidence of bronchopleural fistula in a series of 209 pneumonectomies for lung cancer. Eur J Cardiothorac Surg 1999; 16: 418-423.

234B- d'Amato TA, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 2009;88:1079-85.

235- Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72: 1149-54.

235B- Garrido P, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736-42.

235C- Kunitoh H, et al. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer. Br J Cancer 2007;96:1498-503.

236- Van Schil P. Editorial commentary. Eur Respir Top 2001; 7:37.

237- Bueno R, Richards WG, Swanson SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826-1831.

237B- Van Meerbeeck JP, Kramer GW, Legrand C et al. EORTC-Lung Cancer Group. Does downstaging in patients with IIIA-N2 non-small cell lung cancer and a response to induction chemotherapy influence outcome with surgery or radiotherapy? An exploratory analysis of EORTC 08941. J Clin Oncol 2006; 24 (18s): 7047S

238- López Encuentra A. Complicaciones del tratamiento en pacientes con quimioterapia de inducción previo a resección pulmonar por carcinoma broncogénico. www.mbeneumologia.org

239- Martin J, Abolhoda A, Bains MS, et al. Long-term results of combined modality therapy in resectable non-small cell ung cancer. Proc. ASCO 2001; 20: 311a.

240- Doddoli C, Thomas P, Thirion X, et al. Postoperative complications in relation with induction therapy for lung cancer. Eur J Cardiothorac Surg 2001; 20: 385-390.

241- Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001; 121: 1076-1082.

242- Roberts JR, Eustis C, Devore R, et al. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 2001; 72: 885-888.

Subir

243- Sonobe M, Nakagawa M, Ichinose M, et al. Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 2000; 18: 519-523.

244- Siegenthaler MP, Pisters KM, Merriman KW, et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001; 71: 1105-1111.

244B- Mansour Z, Kochetkova EA, Ducrocq X, Vasilescu MD, Maxant G, Buggenhout A, Wihlm JM, Massard G. Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur J Cardiothorac Surg 2007; 31: 181-5.

244C- Rivera MP, et al. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest 2009;135:1588-95.

244D- Cerfolio RJ, et al. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications. Ann Thorac Surg 2009;88:930-5; discussion 935-6.

244E- Margaritora S, et al. Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery. J Thorac Cardiovasc Surg 2010;139:1457-63.

244F- Krasna MJ, et al. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.  Ann Thorac Surg 2010;89:200-6; discussion 206.

245- Bardet E, Moro-Sibilot D, Le Chevalier T, et al. Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma. Bull Cancer 2001 88: 369-387.

246- Jett JR, Scott WJ, Rivera MP, et al; American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003; 123 (1 Suppl): 221S-225S.

247- Lim ChH, RiceTW, et al. Extended resections in stage T4 NSCLC: Pro.  Movsas B (ed). Controversies in lung cancer. A multidisciplinary approach. Mercel Dekker. New York. 2001; 257-272.

248- Grunenwald DH, Andre F, Le Pechoux C, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122: 796-802.

249- Duque Medina JL, Ramos G, San Roman JA, et al. Evaluación de la afectación tumoral mediastínica (factor T) en cáncer de pulmón por ecografía transesofágica. Arch Bronconeumol 2000; 36: 455-459.

249B- Finley DJ, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol 2010;5:197-205. Erratum in: J Thorac Oncol. 2010;5:926.

249C- Detterbeck FC. Synchronous, separate, and similar. J Thorac Oncol 2010 Feb;5(2):150-2.

250- De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic staging of IIIB non-small cell lung cancer before neoadjuvant therapy. Ann Thorac Surg 1997; 64: 1409-1411.

251- Ginsberg RJ. Treatment of stage III non-small cell lung cancer. Lung Cancer 1994; 11 (sup 2): 144-145.

252- Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001; 49: 973-985.

253- Tombolini V, Bonanni A, Donato V, et al. Radiotherapy alone in elderly patients with medically inoperable stage IIIA and IIIB non-small cell lung cancer. Anticancer Res 2000; 20: 4829-4833.

254- Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 3111: 899-909.
Comentario en: BMJ 1995; 311: 889-890

255- American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.

Subir

256- Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Inter Med 1996; 125: 723-729.
Errata en: Ann Intern Med 1997; 126: 670

257- Robinson LA, Wagner H Jr, Ruckdeschel JC; American College of Chest Physicians. Treatment of stage IIIA non-small cell lung cancer. Chest 2003; 123 (1 Suppl): 202S-220S.

257B- Auperin A, et al. meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 2010;28(:2181-90.

257C- Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

258- Torre M, Quaini E, Chiesa G, et al. Synchronous brain metastasis from lung cancer. Result of surgical treatment in combined resection. J Thorac Cardiovasc Surg. 1988; 95: 994-997.

259- Sa

260- Wronski M, Arbit E, Burt M, et al. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg 1995; 83: 605-616.

261- Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 1996; 109: 271-276.

262- Bonnette P, Puyo P, Gabriel C, et al; Groupe Thorax. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001; 119: 1469-1475.

263- Granone P, Margaritora S, D'Andrilli A, et al. Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg 2001; 20: 361-366.

264- Burt M, Wronski M, Arbit E, et al. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 1992; 103: 399-410.

265- Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001; 122: 548-553.

266- Zabel A, Milker-Zabel S, Thilmann C, et al. Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors.
Lung Cancer 2002; 37: 87-94.

267- Kirsch AJ, Oz MC, Stoopler M, et al. Operative management of adrenal metastases from lung carcinoma. Urology 1993; 42: 716-719.

268- Porte HL, Roumilhac D, Graziana JP, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 1998; 65: 331-335.

269- Beitler AL, Urschel JD, Velagapudi SR, et al. Surgical management of adrenal metastases from lung cancer. J Surg Oncol 1998; 69: 54-57.

270- Porte H, Siat J, Guibert B, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg 2001; 71: 981-985.

271- Bretcha-Boix P, Rami-Porta R, Mateu-Navarro M, et al. Surgical treatment of lung cancer with adrenal metastasis. Lung Cancer 2000; 27: 101-105.

271B- Tanvetyanon T, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008;26:1142-7.

272- Georgoulias V, Papadakis E, Alexopoulos A, et al; Greek Oncology Cooperative Group (GOCG) for Lung Cancer. Platinum-based and non-paltinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.

Subir

273- Socinski MA, Morris DE, Masters GA, et al; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123 (1 Suppl): 226S-243S.

274- Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.
Thorax 2004; 59: 828-36.

274B- NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.

274C- D'Addario G. ESMO Guidelines Working Group.Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:116-9.

275- Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.

276- Ciardiello F, Caputo R, Bianco R, et al. Inhibition of grwth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-1465.

277- Cullen M. Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax 2003; 58: 352-6.

277B- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.

277BB- Reck M, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-34. 

277C- Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.

277D- Crinò L, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010 Aug;11(8):733-40. Epub 2010 Jul 23.

277E- De Marinis F et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009; 4: 1280-8.

278- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.

278B- Noble J. Lung Cancer Disease Site Group of Cancer Care Ontario´s Program in Evidence-based Care. Second-line on subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline. J Thorac Oncol 2006; 1: 1042-58.

278C- Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 4405-11.

278D- Jackman DM, Yeap BY, Lindeman NI, et al. Phase II Clinical Trial of Chemotherapy-Naive Patients >= 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2007 Jan 16; [Epub ahead of print]

278E- Langer CJ. Mind Your Elders: Therapeutic Implications of Epidermal Growth Factor Receptor Inhibition in Older Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2007 Jan 16; [Epub ahead of print]

278F- van Puijenbroek R, Bosquee L, Meert AP, et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 2007; 29: 128-33.

278G- Inoue A, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009 Mar 20;27(9):1394-400.

278H- Mok TS. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Engl J Med 2009; 361:947-57.

Subir

278I- Mitsudomi T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-8.

278J- Maemondo M. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.

278K- Sequist-LV. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer. J Clin Oncol 2010 Oct 12. [Epub ahead of print]

278L- Hirsch FR. The tissue is the issue: personalized medicine for non-small cell lung cancer.Clin Cancer Res 2010; 16: 4909-11.

278M- Kwak EL, et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. N Eng J Med 2010; 363: 1693-703

278N- Choi YL, ALK Lung Cancer Study Group. Brief Report: EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. N Eng J Med 2010; 363: 1734-9

278Q- Hallber B, et al. Crizotinib — Latest Champion in the Cancer Wars? N Eng J Med 2010; 363: 1760-2

279- Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999; 116 (6 Suppl): 525S-530S.

279B- Lim E, et al. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate.  J Thorac Oncol 2008;3:1267-71.

279C- Yu JB, et al.Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215-9.

279D- Schreiber D, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010;116:1350-7.

279E-Vallières E, et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2009;4:1049-1059.

279F- Shepherd FA, et al. Surgery for limited stage small cell lung cancer: time to fish or cut bait. J Thorac Oncol 2010;5:147-9.

279G- Sorensen M. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (suppl 5): v120-v125

279H- Demedts IK. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202-15.

280- Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Eng J Med 1999; 28: 265-271.
Comentario en: N Engl J Med 1999; 340: 2002-3; discussion 2003-4

281- Glisson B, Scott C, Komaki R, et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol 2000; 18: 2990-2995.

282- Laurie SA, Logan D, Markman BR, et al; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 2004; 43: 223-40.

282B- Lee CB, Morris DE, Fried DB, Socinski MA.Current and evolving treatment options for limited stage small cell lung cancer. Curr Opin Oncol 2006 ;18: 162-72. 

283- Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1: 5

284- Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
N Engl J Med 1999; 341: 476-84.

285- Slotman BJ, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Group. J Clin Oncol 2009;27:78-84.

Subir

OTRAS REFERENCIAS:

Publicaciones Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y de Cirugía Torácica (GCCB-S)

1.- Grupo Cooperativo del Carcinoma Broncogénico-SEPAR. Cirugía del Carcinoma Broncogénico en España. Estudio descriptivo. Arch Bronconeumol 1995; 31: 303-309.

2.- José Luis Duque, Guillermo Ramos, et al, and the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Early complications and mortality in surgical treament of bronchogenic carcinoma: A prospective multicenter study. Ann Thorac Surg 1997; 63:944-950.

3.- Angel López Encuentra, José Luis Martín de Nicolas, María Casado López, Eduardo de Miguel Poch, Carmen Marrón Fernández y Grupo Cooperativo de Carcinoma Broncogénico de SEPAR (GCCB-S). Demora en el diagnóstico y en el tratamiento quirúrgico del carcinoma broncogénico. Arch Bronconeumol 1998; 34:123-126.

4.- Ramón Rami Porta, and Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCB-S). Reflections on the Revisions in the lnternatinal System for Staging Lung Cancer. Chest 1998; 113: 1728-1729.

5.- López Encuentra A, and the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Sugery (GCCB-S). Criteria of functional and oncological operabiiity in surgery for lung cancer. A multicenter study. Lung Cancer 1998; 20: 161-168.

6.- Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCB-S). Clinical Tumour Size and Prognosis in Lung Cancer. Eur Respir J 1999; 14: 812-816.

7- Ramón Rami Porta, José Luis Duque, Angel López Encuentra y Grupo Cooperativo de Carcinoma Broncogénico de SEPAR (GCCB-S). The Spanish data base for the staging of lung cancer. Experience of the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Ann Ital Chir 1999; 70:907-908.

8.- Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCBS). Experiencia actual (1993-1997) del Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía Torácica (GCCB-S). Rev Oncol; 2000; 2: 37-41.

9.- Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCB-S). Tumor staging and classification in lung cancer. Lung Cancer 2000; 29: 79-83.

10.- Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCB-S). Estadificación ganglionar intraoperatoria en la Cirugía del Carcinoma Broncogénico. Arch Bronconeumol 2001; 37: 495-503

11.- Angel López Encuentra, and Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).  Comorbidity in operable lung cancer. A multicenter descriptive study on 2992 patients. Lung Cancer 2002; 35: 263-269

12.- Federico González Aragoneses, N. Moreno, P. Leon, E.G. Fontan, E. Folque, and Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 2002; 36: 59-63.

13.- López Encuentra A. Agustín Gómez de la Cámara, A. Varela de Ugarte, N. Mañes, N. Llogregat y Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y de Cirugía Torácica (GCCB-S). El fenómeno Will-Rogers. Migración de estadios en carcinoma broncogénico, tras aplicar criterios de certeza clasificatoria. Arch Bronconeumol 2002; 38: 166-171.

14.- Angel López Encuentra, Agustín Gómez de la Cámara for the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Validation of Central Review Board of Staging prior to Surgery for Non-Small-Cell Lung Cancer- Impact on Prognosis: A Multicenter Study. Respiration 2002; 69: 16-24.

15.- López Encuentra A, Duque-Medina JL, Rami-Porta R, Gómez de la Cámara A, Ferrando P, for the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Staging in lung cancer: Is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1,020 patients. Chest 2002, 121: 1515-1520.

16.- López-Encuentra A, García-Luján R, Rivas JJ, Rodríguez-Rodríguez J, Torres-Lanza J, Varela-Simo G and GCCB-S “Comparison between clinical and pathological staging in 2,994 cases of lung cancer. Ann Thorac Surg 2005; 79: 974-9.

17.- López-Encuentra A, Astudillo J, Cerezal J, González-Aragoneses F, Novoa N, Sánchez-Palencia A, and GCCB-S. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg 2005; 27: 8-13.

18.- Gomez de la Cámara A, López-Encuentra A, Ferrando P, and Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery Heterogeneity of prognostic profiles in non-small cell lung cancer: too many variables but a few relevant. Eur J Epidemiol 2005; 20: 907-14.

19.- Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery. Survival of 2991 patients with surgical lung cancer. The denominator effect in survival. Chest 2005; 128: 2274-81.

20.- Ramón Rami-Porta, Miquel Mateu-Navarro, Jordi Freixinet, Mercedes de la Torre, Antonio Jose Torres-García, Yat-Wah Pun, Antonio Cantó Armengod, on behalf of the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Type of resection and prognosis in lung cancer. Experience of a multicentre study. Eur J Cardio-thorac Surg 2005; 28: 622–628.

Subir

21- Freixinet JL, Julia-Serda G, Rodriguez PM, Santana NB, de Castro FR, Fiuza MD, Lopez-Encuentra A; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spanish multicenter study of 2994 cases. Eur J Cardiothorac Surg 2006; 29: 20-25.

22- López Encuentra A, Pozo Rodríguez F, Martín de Nicolás JL, Villena V, Sayas Catalán J. GCCB-S. Carcinoma bronquioloalvolar en España. Un cáncer de pulmón infrecuente y diferente. Arch Bronconeumol 2006; 42: 399-403.

23- López-Encuentra A, Gómez de la Cámara A, Rami-Porta R, Duque-Medina JL, Martín de Nicolás JL, Sayas J. Previous tumour is a prognostic factor in Stage I Non-small Cell Lung Cancer. Thorax 2007; 62:386-90.

24- Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, Tsuboi M, Vallieres E, Goldstraw P; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2007; 2: 593-602.

25- Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, Tsuchiya R, Vansteenkiste J; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2007; 2: 603-612.

26- Goldstraw P, Crowley J, Chansky K, Dorothy MS, Giroux J, Groome PA, Rami-Porta R, Postmus PE, Rusch VW, and Sobin L, on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification Malignant Tumours. J Thorac Oncol 2007; 2: 706-14

27- Groome PA, Bolejack V, Crowley J, Kennedy C, Krasnik M, Sobin LH, and Goldstraw P, on Behalf of the International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007; 2: 694-705

28- Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF and Yokomise H, on behalf of the International Association for the Study of Lung Cancer International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of< the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2007; 2: 686-693

29- Simón C, Moreno N, Peñalver R, González G, Alvarez-Fernández E, González-Aragoneses F, and the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). The Side of Pneumonectomy Influences Long-Term Survival in Stage I and II Non-Small Cell Lung Cancer. Ann Thorac Surg 2007; 84: 952–8

30- Duque JL, Rami-Porta R, Almaraz A, Castanedo M, Freixinet J, Fernández de Rota A y Grupo Cooperativo del Carcinoma Broncogénico SEPAR (GCCB-S). Parámetros de riesgo en la cirugía del carcinoma broncogénico. Arch Bronconeumol 2007; 43: 143-9

31 - Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007; 2: 1067-77.

32 - López Encuentra A, and GCCB-S. Non–Sized-Based Descriptors in Staging of Stage I Non-small Cell Lung Cancer. Chest 2008; 134: 673-4.

33 - Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P; International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in
the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008; 3:1213-23.

34 - Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3: 457-66.

35 - Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4: 792-801.

36 - Fernández E, de Castro PL, Astudillo J, Fernández-Llamazares J; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery. Bronchial stump infiltration after lung cancer surgery. Retrospective study of a series of 2994 patients. Interact Cardiovasc
Thorac Surg 2009; 9:182-6.

37 - Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:1049-59.

38- López-Encuentra A, López-Ríos F, Conde E, García-Luján R, Suárez-Gauthier A, Mañes N, Renedo G, Duque-Medina JL, García-Lagarto E, Rami-Porta R, González-Pont G, Astudillo-Pombo J, Maté-Sanz JL, Freixinet J, Romero-Saavedra T, Sánchez-Céspedes M, Gómez de la Camara A; on behalf of the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).  Composite anatomic-clinical-molecular prognostic model in non-small-cell lung cancer: a multicenter study of 512 patients. Eur Respir J. 2010 Sep 3. [Epub ahead of print]

Subir

De interés :

A - Ginsberg RJ, Vokes EE, Rosenzweig K. Cancer of the lung. Non-small cell lung cancer. En: DeVita, et al (Eds). Principles and Practice of Oncology, 6th edition. Lppincott Williams and Wilkins. 2001.

B - IASLC-consensus report. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997; 17 (supp 1): 3s-10s.

C - Ettinger DS, et al. NCCN Non-small-cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology Huntingt 1996; 10 (supp 11): 81-111.

D - Evans WK, et al. Lung Cancer Practice Guidelines: Lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group. J Clin Oncol 1997; 15: 3049-3059.

E - Prager D, Cameron R, Ford J, Figlin RA. Bronchogenic Carcinoma. En: Murray, JF, Nadel JA. Textbook of Respiratory Medicine. Third edition. WB Saunders Cia. Filadelfia. 2000; 1415-1451

F - Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.

G - Mountain CF, et al. Regional lymph node classification for lung cancer staging. Chest. 1997; 111: 1718-1723.

H - Naruke T, et al. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 2001; 71: 1759-64

I - The Japan Lung Cancer Society. Classification of lung cancer. First english edition. Kanahara-Co. Tokyo. 2000

J - López Encuentra A and GCCB-S. Criteria of functional and oncological operability in surgery for lung cancer. A multicenter study. Lung Cancer 1998; 20: 161-168.

K - Sanchez-Cespedes M. Dissecting the genetic alterations involved in lung carcinogenesis.
Lung Cancer 2003; 40: 111-21.

L Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.

M - Colm TL, et al. Primary non-small-cell lung cancer: determining the suitability of the patient and tumor for resection. Curr Opin Pulm Med 2000; 6: 391-395.

N - BTS Recommendations to Respiratory Physicians for Organising the Care of Patients with Lung Cancer. Thorax 1998; 53 (sup 1): 1s-8s.

O - ATS-ERS Guidelines. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 1997; 156:320-332.

P - van Meerbeeck JP. Staging of non-small cell lung cancer: consensus, controversies abd challenges. Lung Cancer 2001; 34: 95-107s.

Q - Hansen HH (ed). Textbook of Lung Cancer. IASLC. Martin Dunitz. Londres. 2000.

R - Van Houtte P, Klastersky J, Rocmans P (eds). Progress and Perspectives in the treatment of Lung Cancer. Springer. Berlin. 1999.

S - Deslauriers J, et al. Clinical and surgical staging of non-small cell lung cancer. Chest 2000; 117: 96s-103s.

T - ASCP Survey on Surgical Pathology. Examination of pulmonary resection and biopsy specimens. Am J Clin Pathol 1997; 108: 619-824.

U - Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of resected primary lung carcinomas. Am J Clin Pathol 1995; 104: 371-374.

V - Browman G, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995; 13: 502-512.

W - Browman G, et al. Desarrollo de guías de práctica clínica basadas en la evidencia: de abajo a arriba. Med Clin (Barc) 2001; 116: 267-270.

X - Reif MS, et al. Evidence-based medicine in the treatment of non-small cell lung cancer. Clin Chest Med 2000; 21: 107-120.

Y - Spiro SG (ed). Lung Cancer. Eur Respir Mon. Vol 6. Monograph. 17. November 2001.

Z- Ko B, Sause WT, Byhardt RW, et al. Staging of non-small cell lung carcinoma. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000;215 (Suppl): 1281-94.

Subir

Direcciones de interés :

http://www.aeacap.org

http://www.nationalconsensusproject.org/

http://www.meds.com/pdq/nonsmallcell_pro.html

http://www.lungcancer.org/español/

http://www.nlm.nih.gov/medlineplus/lungcancer.html

http://www.culcasg.org/sub_indice.htm

http://www.cancer.gov/cancertopics/types/lung

http://www.cancer.gov/nlst

http://www.cochrane.es/LCG

http://hiru.mcmaster.ca/ccopgi/lungcpg.html

http://www.cma.ca

http://www.bccancer.bc.ca

http://www.infodoctor.org/rafabravo

http://www.agreecollaboration.org

http://www.uicc.ch

http://www.nice.org.uk

http://www.acosog.org/studies/organ_site/

http://www.mbeneumologia.org

http://www.separ.es (FMC / Curso Estadificación Cáncer)

http://www.LLCG.be

http://www.sign.ac.uk

http://www.acc.org

http://www.americanheart.com

http://www.iaslc.org

http://www.acr.org

http://www.muhealth.org/~ellisfischel/thoracic/lungCancer/

http://www.update-software.com/Cancer/

http://www.clevelandclinicmeded.com/diseasemanagement/pulmonary/lungcancer/lungcancer.htm

http://speakerskit.chestnet.org/dmlc/index.php

http://www.cancerindex.org/clinks2l.htm

http://www.brit-thoracic.org.uk

http://www.rcplondon.ac.uk/pubs/books/lungcancer/index.htm

http://www.cancerbacup.org.uk/Cancertype/Lung

http://www.nccn.org

http://www.icsi.org

http://www.fnclcc.fr

http://www.esmo.org

http://www.ncri.org.uk/

http://www.emedicine.com/med/topic1333.htm

Subir

 
Menu Web
Patrocinadores:
Inicio Volver Arriba Establecer como Página de Inicio Atrás Añadir a mis favoritos
Mejor idea de la década. Diario Médico
Grupo de Medicina Basada en la Evidencia. Servicio de Neumología. Hospital Universitario 12 de Octubre
Grupo de Medicina Basada en la Evidencia
Hospital Universitario 12 de Octubre

Desarrollado por:
Quodem Consultores

Última modificación: 01/04/2014